313 related articles for article (PubMed ID: 38424197)
1. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
Llovet JM; Pinyol R; Yarchoan M; Singal AG; Marron TU; Schwartz M; Pikarsky E; Kudo M; Finn RS
Nat Rev Clin Oncol; 2024 Apr; 21(4):294-311. PubMed ID: 38424197
[TBL] [Abstract][Full Text] [Related]
2. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Hack SP; Spahn J; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Chow P; Qin S
Future Oncol; 2020 May; 16(15):975-989. PubMed ID: 32352320
[TBL] [Abstract][Full Text] [Related]
3. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.
Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L
BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook.
Sahin IH; Khalil L; Millett R; Kaseb A
Chin Clin Oncol; 2021 Feb; 10(1):7. PubMed ID: 33440948
[TBL] [Abstract][Full Text] [Related]
5. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
6. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
Urquijo-Ponce JJ; Alventosa-Mateu C; Latorre-Sánchez M; Castelló-Miralles I; Diago M
World J Gastroenterol; 2024 May; 30(19):2512-2522. PubMed ID: 38817666
[TBL] [Abstract][Full Text] [Related]
7. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.
Samuel M; Chow PK; Chan Shih-Yen E; Machin D; Soo KC
Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD001199. PubMed ID: 19160192
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapies for hepatocellular carcinoma.
Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
[TBL] [Abstract][Full Text] [Related]
10. Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma.
Whitham Z; Hsiehchen D
Surg Oncol Clin N Am; 2024 Jan; 33(1):87-97. PubMed ID: 37945147
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy of liver cancer.
Demir T; Lee SS; Kaseb AO
Adv Cancer Res; 2021; 149():257-294. PubMed ID: 33579425
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
Liu X; Qin S
Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
[TBL] [Abstract][Full Text] [Related]
14. Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?
Dikilitas M
J Gastrointest Cancer; 2020 Dec; 51(4):1193-1196. PubMed ID: 32869146
[TBL] [Abstract][Full Text] [Related]
15. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Ruff SM; Manne A; Cloyd JM; Dillhoff M; Ejaz A; Pawlik TM
Curr Oncol; 2023 Jun; 30(6):5863-5875. PubMed ID: 37366922
[TBL] [Abstract][Full Text] [Related]
16. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapies for hepatocellular carcinoma.
Liu JKH; Irvine AF; Jones RL; Samson A
Cancer Med; 2022 Feb; 11(3):571-591. PubMed ID: 34953051
[TBL] [Abstract][Full Text] [Related]
18. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
[TBL] [Abstract][Full Text] [Related]
19. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
